Research Highlights

Since its inception, the Vancouver Prostate Centre’s research activities have led to valuable new insights, treatments, and intellectual property:

  • We were instrumental in establishing the use of Intermittent Androgen Ablation Therapy as a standard treatment modality for prostate cancer
  • In 2015, the Centre developed a potential new therapeutic that is designed to outsmart cancer and inhibit tumour growth by disabling the androgen receptor where it binds to a specific part of the DNA that is not prone to mutation, opening the possibility of designing drugs that could be effective for a long time
    • The drug candidate was developed using computer-aided drug design (CADD), a technology that evaluates a database of millions of different molecules to identify a handful which may work well as possible treatments
  • My Precision Oncology Program (MyPOP), made possible by infrastructural investment from the Canadian Foundation for Innovation and a generous donation by a private donor, allows for the routine linking of genomic sequencing data with real-time clinical decision making
  • Our annual knowledge output averages 120 peer-reviewed publications and 150 presentations at conferences
  • Since 2008, our Centre has been awarded over $125 million in peer-reviewed research grants from regional, national and international agencies
  • Since 2008 we have initiated 138 new Clinical Trials enrolling 2,886 patients
  • We have a strong record of recruitment of senior staff and faculty promotions
  • The Centre currently had 37 post-doctoral fellows, 35 Ph.D. students and 13 Masters students
  • Since 2008 we have negotiated 56 new contract research agreements with pharmaceutical and biotech companies including Pfizer, Takeda, AstraZeneca, Bayer and Janssen
  • Intellectual Property Activities since 2008 include
    •  294 patent filed/issued
    •  9 Licensing Agreements of IP with Industry (8 drug, 1 biomarker)
      • Our 2015 licensing to Roche was UBC's largest out-licensing deal to date
  • Discoveries at our Centre have led to the creation of several biotech companies, including OncoGeneX (now Achieve Life Sciences) and Aquinox

 

Page updated November 1, 2018

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Movember Foundation 2018

Movember 2018

The Movember Foundation's fundraiser runs from November 1 to 30.  Click here to donate to The Vancouver Prostate Centre team as we join teams across Canada to raise funds for men's health research in the areas of prostate cancer, testicular cancer, mental health and suicide prevention.

Employment

Work at the Vancouver Prostate Centre

Tuesday, November 27, 2018

An innovative new study advances personalized medicine for prostate cancer patients

Drs Chi and Wyatt
Tuesday, October 23, 2018

Three researchers receive Prostate Cancer Canada & Movember Foundation grants for biomarker development